World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
50553
World Ranking
5934
National Ranking
3177

Overview

Ranjana H. Advani is affiliated with Stanford University in the United States and has a substantial research output in the field of Medicine. Their work primarily addresses areas within Pathology and Forensic Medicine, Oncology, Genetics, Immunology, and Pulmonary and Respiratory Medicine. These areas are reflected in the extensive publication record and research topics they have contributed to.

Their main topics of research include:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • T-cell and Retrovirus Studies

Ranjana H. Advani has published numerous papers, with several recent notable publications including:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma, 2022, New England Journal of Medicine
  • The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma, 2021, Cancer Cell
  • The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma, 2021, Annals of Oncology
  • Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results, 2021, Blood

The scientist frequently collaborates with other researchers. Their prominent co-authors include Nancy L. Bartlett, Stephen M. Ansell, Kerry J. Savage, Tatyana Feldman, and Julie M. Vose. These collaborations are evidenced by multiple joint publications.

The venues where Ranjana H. Advani has most frequently published are:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Hematological Oncology
  • Blood Advances
  • Journal of Clinical Oncology

Best Publications

  • The 2016 revision of the World Health Organization classification of lymphoid neoplasms

    Steven H. Swerdlow;Elias Campo;Stefano A. Pileri;Nancy Lee Harris

  • Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Michael L. Wang;Simon Rule;Peter Martin;Andre Goy

  • Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

    Ranjana H. Advani;Joseph J. Buggy;Jeff P. Sharman;Sonali M. Smith

  • Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

    Wyndham H. Wilson;Ryan M. Young;Roland Schmitz;Yandan Yang

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

    Steven P. Treon;Christina K. Tripsas;Kirsten Meid;Diane Warren

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

    Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero

  • PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    Margaretha G.M. Roemer;Ranjana H. Advani;Azra H. Ligon;Yasodha Natkunam

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines

    Ashley A. Powell;AmirAli H. Talasaz;Haiyu Zhang;Marc A. Coram

  • In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

    Joshua D. Brody;Weiyun Z. Ai;Debra K. Czerwinski;James A. Torchia

  • Non-Hodgkin's Lymphomas

    Andrew D. Zelenetz;Ranjana H. Advani;John C. Byrd;Myron S. Czuczman

  • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    Bruce D. Cheson;Stephen Ansell;Larry Schwartz;Leo I. Gordon

  • Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

    Kieron Dunleavy;Stefania Pittaluga;Lauren S. Maeda;Ranjana Advani

  • Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

    Michael L. Wang;Kristie A. Blum;Peter Martin;Andre Goy

  • Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

    Florian Scherer;David M. Kurtz;Aaron M. Newman;Henning Stehr

  • NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.

    Zelenetz Ad;Abramson Js;Advani Rh;Andreadis Cb

  • Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

    David M. Kurtz;Florian Scherer;Florian Scherer;Michael C. Jin;Joanne Soo

  • Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

    Maria Corinna A Palanca-Wessels;Myron Czuczman;Gilles Salles;Sarit Assouline

  • NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines

    Richard T. Hoppe;Ranjana H. Advani;Weiyun Z. Ai;Richard F. Ambinder

Frequent Co-Authors

Richard T. Hoppe
Richard T. Hoppe Stanford University
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Leo I. Gordon
Leo I. Gordon Northwestern University
Randy D. Gascoyne
Randy D. Gascoyne BC Cancer Agency
Ronald Levy
Ronald Levy Stanford University
Saul A. Rosenberg
Saul A. Rosenberg Stanford University
Yasodha Natkunam
Yasodha Natkunam Stanford University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring healthcare careers goes beyond just becoming a physician. Many aspiring professionals consider alternative or complementary pathways through online education. Those interested in advanced nursing roles might begin with asn to np programs, which help registered nurses bridge the gap toward becoming nurse practitioners efficiently.

If you’re passionate about preventative health and wellness, earning a nutritionist online degree can open doors in public health, private practice, or research. Career changers and current healthcare professionals alike are increasingly pursuing flexible academic options.

Leadership positions in hospitals, clinics, and public health agencies require a strong educational foundation. It’s critical to know how to evaluate healthcare administration degree programs to ensure quality and proper accreditation.

For registered nurses seeking advancement, there are now online rn to bsn programs without clinical requirements, offering a practical path to pursue higher education while balancing work.

Each of these options can expand your knowledge, strengthen your credentials, and create new career opportunities in the evolving medical field.

Best Scientists Citing Ranjana H. Advani

Trending Scientists

Recently Published Articles